Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.66 |
| ▸ | MAP3K7 | O43318 | 3/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.51 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.51 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | ITK | Q08881 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21025638 | 0.83 | MAP3K7 (0.69) | EGFRMAP3K7IRAK4IRAK1EPHB4 | |
| SCHEMBL20985290 | 0.81 | EGFR (0.67) | EGFRMAP3K7IRAK4IRAK1EPHB4 | |
| SCHEMBL29336713 | 0.81 | EGFR (0.56) | EGFRMAP3K7IRAK4IRAK1ITK | |
| SCHEMBL16755419 | 0.79 | EGFR (1.00) | EGFRMAP3K7IRAK4IRAK1 | |
| SCHEMBL20985347 | 0.78 | BRD4 (0.40) | EGFR | |
| SCHEMBL20985297 | 0.77 | EGFR (0.57) | EGFRMAP3K7IRAK4IRAK1 | |
| SCHEMBL16755446 | 0.76 | EGFR (0.62) | EGFRMAP3K7IRAK4IRAK1EPHB4 | |
| SCHEMBL16767958 | 0.76 | EGFR (0.61) | EGFRMAP3K7IRAK4IRAK1EPHB4 | |
| SCHEMBL16767967 | 0.76 | EGFR (0.61) | EGFRMAP3K7IRAK4IRAK1EPHB4 | |
| SCHEMBL13500556 | 0.74 | MAP3K7 (0.69) | EGFRMAP3K7IRAK4IRAK1EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20220331297-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2022-10-20 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| EP-3710443-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | Arvinas Operations, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | EGFR 268/4885MAP3K7 536/4885IRAK4 2/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | EGFR 349/4885MAP3K7 533/4885IRAK4 2/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | EGFR 268/4885MAP3K7 536/4885IRAK4 2/4885 |
| US-20220331297-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | EGFR 268/4885MAP3K7 536/4885IRAK4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.